Logo

AstraZeneca's Forxiga (dapagliflozin) Receives EC's Approval for the Treatment of Chronic Kidney Disease in Patients with and without T2D

Share this
AstraZeneca's Forxiga (dapagliflozin) Receives EC's Approval for the Treatment of Chronic Kidney Disease in Patients with and without T2D

AstraZeneca's Forxiga (dapagliflozin) Receives EC's Approval for the Treatment of Chronic Kidney Disease in Patients with and without T2D

Shots:

  • The approval is based on a P-III DAPA-CKD trial that evaluates the efficacy of Forxiga (10mg- qd in addition to SoC) vs PBO in 4304 patients with CKD Stage 2-4 & elevated urinary albumin excretion with & without T2D
  • The results showed 39% reduction in risk of worsening of renal function- ESKD- CV or renal death & 31% from any cause- safety & tolerability were consistent with a well-established safety profile of the therapy
  • The therapy is recently approved in the US for CKD in adults with & without T2D & is currently under review in Japan & other countries globally. The therapy is indicated as an adjunct to diet & exercise to improve glycemic control in adults with T2D & for HF with HFrEF

| Ref: AstraZeneca | Image: The Scientist Magazine

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions